How Sol-Gel is Responding to Covid-19
LEARN MORE

Generic Product Partnerships

In addition to our innovative drug products based on our proprietary delivery technology, we have a portfolio of generic product candidates with favorable commercial agreements.

In Market

acyclovir cream, 5%

(RLD: ZOVIRAX®)

Sales as of January 2019

Pending

ivermectin cream, 1%

(RLD: SOOLANTRA®)

Tentative Approval as of January 2019

halobetasol propionate lotion, 0.01%

(RLD: BRYHALI®)

Filed Paragraph IV Certification January 2020

halobetasol propionate and tazarotene lotion, 0.01%/0.045%

(RLD: DUOBRII®)

Filed Paragraph IV Certification June 2020

5-fluorouracil cream, 5%

(RLD: EFUDEX®)

Bioequivalence Study Completed

All trademarks are the properties of their prospective owners.